1. Home
  2. PD vs VRDN Comparison

PD vs VRDN Comparison

Compare PD & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PagerDuty Inc.

PD

PagerDuty Inc.

HOLD

Current Price

$13.97

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$21.95

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PD
VRDN
Founded
2009
2006
Country
United States
United States
Employees
1155
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
2.1B
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
PD
VRDN
Price
$13.97
$21.95
Analyst Decision
Buy
Strong Buy
Analyst Count
9
14
Target Price
$12.63
$35.46
AVG Volume (30 Days)
1.5M
1.1M
Earning Date
05-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
416.95
N/A
EPS
0.19
N/A
Revenue
$492,546,000.00
$5,706,000.00
Revenue This Year
$3.58
$13.73
Revenue Next Year
$2.88
$279.00
P/E Ratio
$76.00
N/A
Revenue Growth
5.36
N/A
52 Week Low
$5.70
$13.18
52 Week High
$16.91
$34.29

Technical Indicators

Market Signals
Indicator
PD
VRDN
Relative Strength Index (RSI) 61.48 46.44
Support Level $12.78 $21.40
Resistance Level $14.43 $23.84
Average True Range (ATR) 0.51 0.88
MACD -0.03 -0.24
Stochastic Oscillator 58.68 28.87

Price Performance

Historical Comparison
PD
VRDN

About PD PagerDuty Inc.

PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the company derives a majority of its revenue from the United States and the rest from International markets.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Share on Social Networks: